A phase II open-label multicenter study of ONC201 in adults with recurrent histone H3 K27M mutant glioma
Brief description of study
If you have been diagnosed with recurrent glioma (a type of brain tumor), you may be qualified to participate in this study evaluating the investigational drug ONC201. The main goal of this phase II study is to see whether the drug ONC201 is safe and effective in treating recurrent glioma (a type of brain cancer) with a specific mutation called H3 K27M.
Clinical Study Identifier: s17-01023
ClinicalTrials.gov Identifier: NCT03295396
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
